FTC rules drug companies illegally delayed generics

12/19/2003 | Forbes

The U.S. Federal Trade Commission (FTC) issued an administrative opinion concluding that Schering-Plough, Upsher-Smith Laboratories and American Home Products entered into illegal agreements to delay the entry of generic competitors of K-Dur 20 into the market. It said Schering-Plough, the brand-name manufacturer, arranged with Upsher and AHP, generic makers, to deter their production; Schering-Plough said it would appeal the ruling.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC